Sanuwave Health (NASDAQ:SNWV) Issues Earnings Results

Sanuwave Health (NASDAQ:SNWV) released its quarterly earnings results on Tuesday. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03), FiscalAI reports. The business had revenue of $9.62 million for the quarter, compared to the consensus estimate of $9.60 million. Sanuwave Health had a net margin of 26.64% and a negative return on equity of 141.56%.

Sanuwave Health Price Performance

NASDAQ SNWV traded up $0.04 on Tuesday, reaching $16.04. The company had a trading volume of 155,136 shares, compared to its average volume of 73,070. The company has a quick ratio of 1.05, a current ratio of 1.38 and a debt-to-equity ratio of 10.08. The stock has a market capitalization of $137.94 million, a PE ratio of -100.24 and a beta of 1.37. The firm’s 50 day moving average price is $19.33 and its 200 day moving average price is $25.85. Sanuwave Health has a 12 month low of $15.35 and a 12 month high of $46.58.

Hedge Funds Weigh In On Sanuwave Health

Several institutional investors have recently bought and sold shares of SNWV. Legal & General Group Plc bought a new position in Sanuwave Health during the second quarter valued at $26,000. BNP Paribas Financial Markets bought a new position in Sanuwave Health during the second quarter valued at $46,000. Russell Investments Group Ltd. bought a new position in Sanuwave Health during the third quarter valued at $67,000. New York State Common Retirement Fund bought a new position in Sanuwave Health during the second quarter valued at $102,000. Finally, JPMorgan Chase & Co. bought a new position in Sanuwave Health during the second quarter valued at $109,000. Institutional investors own 42.53% of the company’s stock.

Wall Street Analysts Forecast Growth

SNWV has been the subject of several analyst reports. Zacks Research downgraded Sanuwave Health from a “hold” rating to a “strong sell” rating in a report on Monday, March 30th. Wall Street Zen cut shares of Sanuwave Health from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Weiss Ratings upgraded shares of Sanuwave Health from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, March 27th. Finally, Roth Mkm reiterated a “buy” rating and set a $47.00 price target (down from $53.00) on shares of Sanuwave Health in a report on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Sanuwave Health has a consensus rating of “Moderate Buy” and a consensus price target of $51.00.

About Sanuwave Health

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.